DKF-MA102

Phase 3Small molecule

DDongkook Pharmaceutical Co., Ltd.

DKF-MA102 is one of 22 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Prostate CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Mekinist

Novartis

Preclinical

3 2

DKF-MA102

DDongkook Pharmaceutical Co., Ltd.

Phase 3

1 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Viagra

VViatris Specialty LLC

Preclinical

1 6

Duragesic

CCephalon

Preclinical

1 7

Triptorelin Pamoate

Ipsen

Preclinical

2 8

Ifex

BBaxter Healthcare Corporation

Xylocaine

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

Recruiting·DDongkook Pharmaceutical Co., Ltd.·Phase 3·NCT06490328·154 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DKF-MA102. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DKF-MA102 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DKF-MA102. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dongkook Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: DDongkook Pharmaceutical Co., Ltd.

DKF-MA102

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News